Cite
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
MLA
Thierry May, et al. “Efficacy and Safety of Raltegravir in Treatment-Experienced HIV-1-Infected Patients Switching from Enfuvirtide-Based Regimens: 48 Week Results of the Randomized EASIER ANRS 138 Trial.” The Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, June 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b14f1745b15001ace4ee7c2a56a95a88&authtype=sso&custid=ns315887.
APA
Thierry May, Renaud Verdon, Constance Delaugerre, Isabelle Madelaine-Chambrin, B. Balkau, Jean-Michel Molina, Vincent Calvez, M. Bourlière, Isabelle Charreau, Daniel Sereni, S. Gallien, Jean-Pierre Aboulker, Joséphine Braun, Jacques Reynes, Pierre de Truchis, François Jeanblanc, & M. Korzek. (2011). Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. The Journal of Antimicrobial Chemotherapy, 66(9).
Chicago
Thierry May, Renaud Verdon, Constance Delaugerre, Isabelle Madelaine-Chambrin, B. Balkau, Jean-Michel Molina, Vincent Calvez, et al. 2011. “Efficacy and Safety of Raltegravir in Treatment-Experienced HIV-1-Infected Patients Switching from Enfuvirtide-Based Regimens: 48 Week Results of the Randomized EASIER ANRS 138 Trial.” The Journal of Antimicrobial Chemotherapy 66 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b14f1745b15001ace4ee7c2a56a95a88&authtype=sso&custid=ns315887.